Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
-
Continues to progress Phase 1 clinical trial of ONCR-177, company’s lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate; on track to report initial interim data in 4Q’21Nominated...
-
-- Former Merck executive brings extensive experience in corporate development, licensing and financial evaluation, and expertise advising clinical stage public biopharmaceutical companies -- ...
-
-- Renowned academic and industry leader brings deep expertise in oncology translational research and drug development, including pioneering work at Merck on KEYTRUDA® (pembrolizumab) -- CAMBRIDGE,...
-
Virtual event will take place on June 21, 2021 from 1:00 – 2:30 p.m. ETOncorus’ novel approach leverages selectively self-amplifying vRNA encoding for oncolytic viruses encapsulated within lipid...
-
Pioneering Synthetic vRNA immunotherapies that are composed of self-amplifying vRNA encoding for oncolytic viruses encapsulated within lipid nanoparticles (LNPs)Novel approach engineered to produce a...
-
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
-
-- Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H’21 -- ...
-
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
2020 marked year of notable progress for Oncorus. Key highlights included: Transitioned to clinical-stage company with initiation of Phase 1 clinical trial of lead viral immunotherapy candidate,...
-
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to...